Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-{4-[4-(4-chlorophenyl)piperidin-4-yl]phenyl}-9H-purine is an experimental small molecule compound belonging to the diphenylmethane class, with a molecular formula of C22H20ClN5 and a molecular weight of approximately 389.88 g/mol[1][2][8]. It has not been approved for any therapeutic use and is not known to be in clinical development for any disease. The compound has been identified as interacting with the cAMP-dependent protein kinase catalytic subunit alpha (PRKACA), but its pharmacological action remains uncharacterized[1][3]. No clinical trials or indications are currently associated with this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-{4-[4-(4-chlorophenyl)piperidin-4-yl]phenyl}-9H-purine.